NAD+: Not a Peptide — What the Coenzyme Evidence Shows

Nicotinamide adenine dinucleotide (NAD+) is not a peptide. It contains no amino acids: it is made of two nucleotides joined by phosphate groups. It appears in peptide catalogues because it is studied in the same metabolic and ageing research context, but its chemistry, handling and regulation are different.

Mechanism under study

NAD+ is an essential electron carrier in energy metabolism and a substrate for enzymes such as sirtuins, PARPs involved in DNA repair, and CD38. Tissue NAD+ levels decline with age in many animal studies and in some human tissues, which led to the hypothesis that restoring NAD+ might support healthy ageing. The body makes NAD+ from precursors including niacin, nicotinamide, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

State of the human evidence

Multiple randomised trials show that oral NR and NMN reliably raise NAD+ levels in blood. Effects on clinical outcomes have been modest and inconsistent: some small trials reported changes in specific metabolic or muscle measures, while others found no meaningful improvement in insulin sensitivity, blood pressure or physical function. Evidence for intravenous NAD+ infusions comes mainly from small, uncontrolled studies and does not establish clinical benefit.

Limitations, risks and adverse effects

• Raising a blood biomarker is not the same as improving health outcomes; long-term trials are lacking.
• Oral precursors were generally well tolerated in trials, with mild gastrointestinal effects reported.
• Rapid intravenous NAD+ administration has been associated with flushing, nausea, abdominal cramping and chest tightness.
• Because NAD+ metabolism supports cell proliferation, researchers continue to examine its relationship with cancer biology; the question is open.

Regulatory status by region

NAD+ itself is not an approved medicine for ageing or metabolic conditions in the EU, the UK or the US. Precursors are regulated mainly as foods or supplements, and their status differs: in the EU, nicotinamide riboside chloride is authorised as a novel food under defined conditions, while NMN has not been authorised as a novel food. In the United States, the regulatory position of NMN as a dietary supplement has been reviewed and changed by the FDA in recent years. Niacin and nicotinamide are long-established vitamins.

Bottom line

NAD+ biology is real and important, but the leap from higher blood levels to proven health benefits has not been made. For laboratory context, see our NAD+ research profile; for a genuinely peptide-based mitochondrial signal, see our MOTS-c evidence review.